It is widely recognized that many people with chronic obstructive pulmonary disease (COPD) are undiagnosed, including some with significant airflow obstruction. The best available data suggest that the prevalence of physiologically defined COPD in adults aged 40 years is 9%--10% ([@b9-copd-1-343]). In their study of randomly selected individuals aged 60 to 74 years from a UK general practice register, [@b5-copd-1-343] found that there were 2.69 "true" cases of COPD for each diagnosed case, with an overall prevalence of 6.2% with undiagnosed COPD. A similar study of a random sample of the general population aged over 64 years in Finland found 1.99 and 1.62 true cases of COPD for each diagnosed case in men and women, respectively (Isoha et al 1994). Other studies have compared the prevalence of respiratory symptoms with patient-reported diagnoses and found a ratio of true COPD cases to self-reported diagnoses ranging from approximately 1.5 to 4 ([@b15-copd-1-343]; [@b16-copd-1-343]; [@b24-copd-1-343]; [@b14-copd-1-343]). Most recently a study in Manchester by [@b7-copd-1-343] found that nearly two thirds of patients with spirometrically confirmed COPD had no prior diagnosis of COPD and nearly half of these had severe airflow obstruction.

Some of these patients have no diagnosis of airways disease at all and others are misdiagnosed as asthmatics. It has been suggested that COPD and asthma are simply different phenotypes of a common obstructive disease; the so called Dutch Hypothesis ([@b2-copd-1-343]). This has led to the suggestion that differentiation is unnecessary, particularly as treatment uses similar drugs ([@b13-copd-1-343]). However, most evidence suggests that asthma and COPD have a different etiology and pathophysiology, and require different management ([@b1-copd-1-343]). Although similar drugs are used in both diseases they are used in different sequences and with different doses. For example, low dose inhaled steroids are essential in patients with asthma whose symptoms are persistent, whilst in COPD inhaled steroids are principally recommended in patients with an forced expiratory volume in one second (FEV~1~) of \<50% and experiencing frequent exacerbations. The evidence for their efficacy is based on use at a high dose ([@b6-copd-1-343]; [@b19-copd-1-343]).

Perhaps the most important reason for distinguishing the two conditions is the fact that they have very different prognoses. Most asthmatics maintain normal or near normal lung function and have a normal life expectancy ([@b18-copd-1-343]) whereas lung function in patients with COPD declines inexorably and patients have a reduced life expectancy ([@b22-copd-1-343]).

Making a diagnosis of COPD and its differentiation from asthma presents an important challenge for primary care practitioners. Previously, many practitioners used reversibility testing as a sensitive and specific test to differentiate COPD from asthma. There is now clear evidence that, unless interpreted in the light of the clinical assessment of the diagnosis, reversibility testing alone cannot differentiate asthma from COPD. The results are not reproducible over time ([@b3-copd-1-343]) and are highly dependent on the method used to assess reversibility ([@b20-copd-1-343]; [@b8-copd-1-343]). Some degree of fixed airflow obstruction occurs in up to 30% of patients with asthma ([@b12-copd-1-343]) whilst many patients with COPD show a significant bronchodilator response despite having no clinical features of asthma ([@b23-copd-1-343]). Moreover, if a fixed threshold such as a 15% improvement in FEV~1~ is used reversibility testing has been found to have a sensitivity of only 44% for detecting asthma and a specificity of only 72% for distinguishing asthma from COPD ([@b17-copd-1-343]).

It has been pointed out that the recommendation in the National Institute for Clinical Excellence guideline that routine reversibility testing should not be relied upon to differentiate COPD from asthma ([@b19-copd-1-343]) makes it more difficult for primary care practitioners to diagnose COPD. Prior to this recommendation, some clinicians preferred to use a flawed test to make a wrong diagnosis easily rather than putting the effort in to making a correct diagnosis ([@b7-copd-1-343]).

When making a diagnosis, thinking of possible diagnoses is the first and possibly the most important step. If a diagnosis is not considered then subsequent history taking, examination, and investigations will be markedly less likely to lead to that diagnosis. The results of the CADRE ([C]{.ul}OPD and [A]{.ul}sthma [D]{.ul}iagnostic/Management [Re]{.ul}assessement) study reported by [@b21-copd-1-343] in this edition of International Journal of COPD highlights this issue. The authors found that a working diagnosis of asthma was more likely to be made in younger patients, women, and nonsmokers. The authors found that it was much more common to revise the diagnosis of asthma than to revise the diagnosis of COPD after clinical review and spirometry.

What are the implications for practice? The CADRE study supports the need to take a good clinical history when making a diagnosis and to use spirometry to confirm the diagnosis. Since this work was undertaken, the availability of spirometry in primary care has increased considerably in the UK ([@b10-copd-1-343]) and its routine use has been encouraged by contractual arrangements with general practitioners. The CADRE study also reminds us that COPD is becoming more common in women and suggests that there was a tendency to over-diagnose asthma and under-diagnose COPD in primary care. Reluctance to make the diagnosis of COPD and gender bias when diagnosing COPD are well recognized ([@b4-copd-1-343]) and these must be overcome if the missing millions with COPD are to be identified.
